Facebook
Twitter
Prescription Drug Issues (quality, safety, access, cost)
A leader in building broad collaborations around state and national prescription drug issues, Community Catalyst has developed model public policies, legal tools and campaign strategies that consumers, physician organizations, health plans and other concerned groups have successfully deployed in their advocacy work. We have spearheaded innovative state campaigns to improve policies on conflicts of interest, better access and evidence-based prescribing. These successes have in turn created opportunities, pressure and models for federal action. For more details, please visit the Prescription Access and Quality project page.
- June 05, 2013 Conflict-of-Interest Curriculum Toolkit This toolkit provides the rationale for teaching about conflict of interest in medical schools and residency programs and a succinct overview of the competencies learners should achieve, along with the theory supporting various educational approaches.
- June 05, 2013 Toolkit on Continuing Medical Education This toolkit addresses the issue of pharmaceutical and device industry support for continuing medical education. It outlines concerns about the effects of such support on the information that clinicians receive through CME programs and subsequent bias in prescribing decisions.
- November 04, 2011 Protecting Seniors by Ensuring Safe Drug Manufacturing The U.S. pharmaceutical industry produces vital and innovative medicines that contribute to the health and independence of seniors. However, vulnerabilities in the manufacturing processes and distribution system for these products have become a critical public health concern.
- October 24, 2011 Letter to Secretary Sebelius Regarding Disclosure of Industry Payment to Physicians and Teaching Hospitals Under the Physician Payments Sunshine Provision, manufacturers of drugs, devices, biologics or medical supplies, or their subsidiaries that sell these products in the United States, must report to Health and Human Services certain payments made to physicians and teaching hospitals.
- October 24, 2011 Letter to Secretary Sebelius Regarding Disclosure of Industry Payment to Physicians and Teaching Hospitals Under the Physician Payments Sunshine Provision, manufacturers of drugs, devices, biologics or medical supplies, or their subsidiaries that sell these products in the United States, must report to Health and Human Services certain payments made to physicians and teaching hospitals.
- June 24, 2011 Community Catalyst Statement on Supreme Court Decision Striking Down Vermont Law Protecting Prescription Records
- May 11, 2011 Letter in Support of Drug Safety Enhancement Act Eight national organizations in addition to Community Catalyst sent this letter to all members of the House of Representatives in support of the Drug Safety Enhancement Act of 2011, HR 1483.
- March 02, 2011 Amicus Brief, filed with the U.S. Supreme Court, in Support of Vermont Law Banning Data Mining
- March 01, 2011 Data mining amicus brief filed with the Supreme Court Amicus brief filed with the Supreme Court regarding the role of data mining in driving illegal promotions of off-label drugs by Community Catalyst, Prescription Access Litigation, Health Care for All MA and AFSCME D.C.
- November 01, 2010 Comments on FDA Supply Chain Strategic Priority Comments of Community Catalyst and six additional organizations on the FDA's draft strategic priority of strengthening the safety and integrity of the global supply chain.
- October 27, 2010 Safety of Over-the-Counter Drugs Fact Sheet In recent years there have been a number of incidents pointing to the safety concerns of over-the-counter drugs. In 2009, a record 1,742 drugs -- including 50 dietary supplements -- were recalled, four times the number recalled in 2008.1 Many of these involved over-the-counter (OTC) medications available without prescription.
- October 27, 2010 Safety of Over-the-Counter Drugs In recent years there have been a number of incidents pointing to the safety concerns of over-the-counter drugs. In 2009, a record 1,742 drugs — including 50 dietary supplements — were recalled, four times the number recalled in 2008.1 Many of these involved over-the-counter (OTC) medications available without prescription.
- October 07, 2010 Safety of the Prescription Drug Supply Fact Sheet
- October 07, 2010 Drug Safety and Accountability Act of 2010 Fact Sheet
- October 07, 2010 Exposing the Gaps Fact Sheet
- June 25, 2010 Prescription Access Litigation Comments on FDA's notice on Direct-to-Consumer Advertisements Community Catalyst's PAL coalition and 22 other groups weigh in on FDA's notice on making risks clear, conspicuous and neutral in broadcast drug ads
- November 13, 2009 The MassHealth Pharmacy Program: Implementation Report The MassHealth Pharmacy Program Implementation report, presented at the Massachusetts Health Policy Forum Nov. 13, found that the Massachusetts model is a successful approach to clinically rigorous pharmaceutical cost containment that has been met with acceptance among providers and advocates.
- August 06, 2009 Consumer Survey
- April 02, 2009 Academic Detailing Fact Sheet
- March 16, 2009 Sample Prescription Medications Fact Sheet
- February 12, 2009 Why Small Gifts Matter Fact Sheet
- February 01, 2009 The Case for Disclosure
- January 20, 2009 Pharmaceutical Industry Marketing Fact Sheet
- December 18, 2008 Non-physician Prescribers and Pharmaceutical Industry Interactions
- November 19, 2008 Prescription Data Mining Fact Sheet
- September 26, 2008 Comments to FDA on Limitations and Risks of Direct-to-Consumer Advertising
- September 12, 2008 Regulating Industry Payments to Physicians: Identifying & Minimizing Conflicts Of Interest: Fact Sheet
- July 11, 2008 Prescriber Education Model Legislation
- July 11, 2008 PhRMA Marketing Code on Interactions with Healthcare Professionals: Old vs. New
- June 24, 2008 Data Mining Amicus Curiae: IMS Health v. Sorrell
- May 07, 2008 Data Mining and Medicaid Fact Sheet
- April 21, 2008 Comments to FDA on Good Journal Reprint Practices
- March 26, 2008 Advancing Efficient Management and Purchasing of Prescription Drugs
- March 12, 2008 Cost-Effectiveness of Prescriber Education (Academic Detailing) Programs
- January 18, 2008 Model Legislation: Prescription Drug and Medical Device Marketing Restrictions and Disclosure Act The Prescription Project provides a brief on medical device marketing restrictions and the Disclosure Act
- October 18, 2007 Risk with No Benefit: The Marketing of Over-the-Counter Cough and Cold Medications for Children
- August 31, 2007 The Constitutional Battle over State Regulation of Data Mining
- August 31, 2007 Legal Analysis: The Constitutional Battle Over State Regulation of Data Mining This article provides a brief explanation of the legal and policy background for state regulation of data mining and “detailing” in the pharmaceutical industry and explains some recent state responses to the New Hampshire decision.
- August 30, 2007 | from The Prescription Project A Fact Sheet on Data Mining A fact sheet on data mining
- August 30, 2007 | from The Prescription Project Data Mining: Myths and Rebuttals Frequently asked questions about data mining
- July 07, 2007 Data Mining Amicus Curiae: IMS Health v. Ayotte